A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess pharmacokinetics of tiotropium + olodaterol
fixed-dose combination (2.5 µg/ 5 µg, 5 µg/ 5 µg) delivered by the RESPIMAT inhaler after 3
weeks once daily treatment in Japanese patients with COPD.